Clinical Trials Logo

Clinical Trial Summary

This is a phase II randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed tomography (PET/CT) and multi- parameter Magnetic Resonance Imaging (MRI) guided simultaneous integrated boost for prostate cancer.


Clinical Trial Description

Local recurrences of prostate cancer following radiotherapy often originate from the primary tumor site. Therefore,focal boost to the primary gross tumor has been proposed to increase biochemical disease-free survival (bDFS) without increasing toxicity. The higher relative biological effectiveness (RBE) and greater cytocidal effect on the intrinsic radiation resistant cancer cells offer carbon ion radiotherapy (CIRT) advantages over conventional radiotherapy. In this study, carbon ion were used to treat localized prostate cancer and simultaneous integrated boost to the gross tumor in the prostate specific membrane antigen (PSMA) PET/CT and multi- parameter MRI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05010343
Study type Interventional
Source Shanghai Proton and Heavy Ion Center
Contact
Status Recruiting
Phase Phase 2
Start date October 15, 2020
Completion date July 1, 2028

See also
  Status Clinical Trial Phase
Completed NCT03996005 - MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer N/A
Withdrawn NCT02159690 - A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Phase 2
Completed NCT00196781 - Treatment Decision Making in Early-Stage Prostate Cancer Phase 3
Recruiting NCT03821246 - Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Phase 2
Active, not recruiting NCT03814252 - Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer N/A
Completed NCT01931046 - Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer Phase 1/Phase 2
Completed NCT01714219 - Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy N/A
Active, not recruiting NCT03315754 - Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. Phase 2
Recruiting NCT06325995 - Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer N/A
Recruiting NCT06051942 - PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs N/A
Completed NCT02297386 - [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer Phase 1
Not yet recruiting NCT06117059 - The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance N/A
Withdrawn NCT04225299 - Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer Phase 3
Recruiting NCT06054867 - PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System N/A
Active, not recruiting NCT02435472 - Active Surveillance Exercise Clinical Trial N/A
Completed NCT00717613 - Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting N/A
Completed NCT02662673 - Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device N/A
Recruiting NCT05155046 - 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy Phase 2
Completed NCT01902680 - Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant. Phase 2
Recruiting NCT00651417 - Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue Phase 2